Johnson & Johnson: Still One Of The More Expensive Pharmaceutical Companies
Summary: Johnson & Johnson reported mediocre results for fiscal 2022, but is expecting low-to-mid single
Summary: Johnson & Johnson reported mediocre results for fiscal 2022, but is expecting low-to-mid single
Summary: JNJ is a dividend king for having increased their dividend for 50+ consecutive years.
Summary: Dividends have remained decent. However, the company has greatly lagged the broad S&P index.
Summary: The Abiomed acquisition enhances JNJ’s positioning in one of the most lucrative markets around
Summary: Investors have been abandoning Johnson & Johnson stock in droves as mounting legal issues
Summary: Johnson & Johnson’s talc lawsuit issues continue. Looming loss of exclusivity on JNJ’s top
Summary: Recession is coming and with it plenty of scary headlines about crashing stock prices
Summary: To limit the legal liabilities related to talc, Johnson & Johnson has adopted a
Summary: Johnson & Johnson has seen its shares drop to a 52-week low. The company
Summary: At the end of 2023, Johnson & Johnson will be spinning off its Consumer